Document Type
Article
Publication Date
1-29-2024
Original Citation
Habowski A,
Budagavi D,
Scherer S,
Aurora A,
Caligiuri G,
Flynn W,
Langer E,
Brody J,
Sears R,
Foggetti G,
Arnal Estape A,
Nguyen D,
Politi K,
Shen X,
Hsu D,
Peehl D,
Kurhanewicz J,
Sriram R,
Suarez M,
Xiao S,
Du Y,
Li X,
Navone N,
Labanca E,
Willey C.
Patient-Derived Models of Cancer in the NCI PDMC Consortium: Selection, Pitfalls, and Practical Recommendations. Cancers (Basel). 2024;16(3):565.
Keywords
JGM
JAX Source
Cancers (Basel). 2024;16(3):565.
ISSN
2072-6694
PMID
38339316
DOI
https://doi.org/10.3390/cancers16030565
Grant
Support was provided by an NCI-funded Patient-Derived Models of Cancer Consortium formed by 10 funded U01 projects (U01CA224013, U01CA217514, U01CA217613, U01CA224012, U01CA223976, U01CA224044, U01CA228608, U01CA217617, U01CA235747, and U01CA217456) to the following institutes involved in this consortium: Cold Spring Harbor Laboratory, Jackson Laboratory, Duke University, Lurie Children’s Hospital of Chicago Northwestern University, Oregon Health & Science University, University of Alabama at Birmingham, University of California San Francisco, University of Texas MD Anderson Cancer Center, University of Texas Southwestern Medical Center, University of Utah, and Yale University.
Abstract
For over a century, early researchers sought to study biological organisms in a laboratory setting, leading to the generation of both in vitro and in vivo model systems. Patient-derived models of cancer (PDMCs) have more recently come to the forefront of preclinical cancer models and are even finding their way into clinical practice as part of functional precision medicine programs. The PDMC Consortium, supported by the Division of Cancer Biology in the National Cancer Institute of the National Institutes of Health, seeks to understand the biological principles that govern the various PDMC behaviors, particularly in response to perturbagens, such as cancer therapeutics. Based on collective experience from the consortium groups, we provide insight regarding PDMCs established both in vitro and in vivo, with a focus on practical matters related to developing and maintaining key cancer models through a series of vignettes. Although every model has the potential to offer valuable insights, the choice of the right model should be guided by the research question. However, recognizing the inherent constraints in each model is crucial. Our objective here is to delineate the strengths and limitations of each model as established by individual vignettes. Further advances in PDMCs and the development of novel model systems will enable us to better understand human biology and improve the study of human pathology in the lab.
Comments
© 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https:// creativecommons.org/licenses/by/ 4.0/).